Craig C. Hopkinson Sells 144,419 Shares of Alkermes plc (NASDAQ:ALKS) Stock

Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the transaction, the executive vice president now directly owns 57,875 shares of the company's stock, valued at $2,056,298.75. The trade was a 71.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alkermes Trading Up 0.2 %

ALKS stock traded up $0.06 during trading on Tuesday, reaching $35.95. 486,545 shares of the stock were exchanged, compared to its average volume of 1,690,007. The business has a 50 day moving average price of $30.49 and a 200-day moving average price of $28.87. The firm has a market capitalization of $5.82 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 1.83 and a beta of 0.49. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $36.45. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22.

Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. On average, research analysts predict that Alkermes plc will post 2.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. boosted its holdings in shares of Alkermes by 4.3% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 601,129 shares of the company's stock valued at $17,288,000 after buying an additional 25,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Alkermes by 14.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 462,241 shares of the company's stock valued at $13,294,000 after buying an additional 56,859 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Alkermes by 17.6% in the 4th quarter. Squarepoint Ops LLC now owns 223,069 shares of the company's stock valued at $6,415,000 after buying an additional 33,419 shares in the last quarter. Stempoint Capital LP boosted its holdings in shares of Alkermes by 752.4% in the 4th quarter. Stempoint Capital LP now owns 416,968 shares of the company's stock valued at $11,992,000 after buying an additional 368,050 shares in the last quarter. Finally, RTW Investments LP boosted its holdings in shares of Alkermes by 13.6% in the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock valued at $217,363,000 after buying an additional 903,802 shares in the last quarter. Institutional investors and hedge funds own 95.21% of the company's stock.

Wall Street Analyst Weigh In

ALKS has been the subject of a number of recent analyst reports. The Goldman Sachs Group lifted their price objective on shares of Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday. JPMorgan Chase & Co. dropped their target price on shares of Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a research report on Friday, October 25th. HC Wainwright reiterated a "neutral" rating and issued a $46.00 target price on shares of Alkermes in a research report on Thursday, February 13th. Mizuho lifted their target price on shares of Alkermes from $35.00 to $40.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Finally, StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $37.25.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.